David Kirn Sells 42,608 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 42,608 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $12.87, for a total transaction of $548,364.96. Following the transaction, the insider directly owned 899,877 shares of the company’s stock, valued at $11,581,416.99. The trade was a 4.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

David Kirn also recently made the following trade(s):

• On Friday, July 10th, David Kirn sold 15,725 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.03, for a total transaction of $189,171.75.
• On Monday, June 22nd, David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.47, for a total transaction of $1,201,390.62.
• On Monday, June 1st, David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.02, for a total transaction of $19,258.44.

4D Molecular Therapeutics Trading Down 0.2%

Shares of FDMT opened at $11.68 on Thursday. The firm has a market cap of $610.58 million, a PE ratio of -4.54 and a beta of 2.70. The firm has a fifty day simple moving average of $10.33 and a two-hundred day simple moving average of $9.41. 4D Molecular Therapeutics, Inc. has a 1-year low of $4.14 and a 1-year high of $14.00.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The firm had revenue of $3.05 million for the quarter, compared to the consensus estimate of $2.59 million. As a group, research analysts forecast that 4D Molecular Therapeutics, Inc. will post -4.14 EPS for the current fiscal year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Evergreen Quality Fund GP Ltd. purchased a new position in shares of 4D Molecular Therapeutics during the 4th quarter valued at $7,136,000. Simplify Asset Management Inc. purchased a new stake in 4D Molecular Therapeutics in the 1st quarter worth $656,000. Baker BROS. Advisors LP bought a new stake in 4D Molecular Therapeutics during the fourth quarter valued at about $3,568,000. Armistice Capital LLC raised its holdings in 4D Molecular Therapeutics by 76.6% during the fourth quarter. Armistice Capital LLC now owns 1,936,000 shares of the company’s stock valued at $14,520,000 after acquiring an additional 840,000 shares during the period. Finally, Landing Point Financial Group LLC purchased a new position in shares of 4D Molecular Therapeutics in the fourth quarter valued at about $142,000. Institutional investors own 99.27% of the company’s stock.

Analyst Ratings Changes

FDMT has been the subject of a number of recent research reports. Royal Bank Of Canada boosted their price target on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, March 19th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. Jefferies Financial Group restated a “buy” rating and set a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Finally, Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $29.88.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.